Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 19 of 19 results for infliximab crohns disease

  1. Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)

    Evidence-based recommendations on vedolizumab (Entyvio) for treating moderate to severe ulcerative colitis in adults.

    Technology appraisal guidance
    Published
    5 June 2015
    View recommendations

    Sections for TA342

  2. Pouchitis: rifaximin (ESUOM30)

    Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making

    Evidence summary
    Published
    25 March 2014

  3. Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease (MIB132)

    NICE has developed a medtech innovation briefing (MIB) on point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease .

    Medtech innovation briefing
    Published
    4 December 2017

  4. The clinical effectiveness and cost effectiveness of infliximab for Crohn's disease (TA40)

    This guidance has been updated and replaced by NICE technology appraisal guidance 187.

    Withdrawn guidance